Abstract
BackgroundWith the incidence of breast cancer rising worldwide, we are evaluating the iBreastExam (iBE) (UE LifeSciences Inc.), a handheld breast scanning device that can be utilized by community health workers to screen for breast abnormalities. The purpose of this study is to determine the sensitivity of the iBE in a population undergoing diagnostic breast imaging.MethodsAdult patients presenting to a breast imaging center for a diagnostic workup were eligible. Patients underwent an iBE exam performed by a trained ultrasound technician followed by their indicated imaging. Demographic, imaging, and biopsy data were recorded.ResultsSeventy-eight iBE exams were completed, 77 females and one male with a mean age of 42 (21–79). All patients were evaluated by ultrasound, 52 had diagnostic mammography and 39 had biopsies. Imaging and/or biopsy confirmed a mass (fibroadenoma, cyst, papilloma, myofibroblastoma, fat necrosis, DCIS, or cancer) in 60 patients. Twelve patients had a cancer diagnosed. In total, 342 quadrants were scanned, 77 quadrants had lesions confirmed on imaging, and iBE correctly identified 66 lesions for a sensitivity of 86 % and specificity of 89 %.ConclusionsThis validation study demonstrated excellent sensitivity of iBE for the identification of clinically significant lesions in patients presenting for diagnostic imaging.Trial registrationA Cost-Effective Handheld Breast Scanner for Use in Low Resource Environments: A Validation Study: NCT02814292.
Highlights
With the incidence of breast cancer rising worldwide, we are evaluating the iBreastExam (UE LifeSciences Inc.), a handheld breast scanning device that can be utilized by community health workers to screen for breast abnormalities
The iBreastExam device was developed as a pre-screening tool that could identify women in need of further breast imaging without requiring extensive breast screening infrastructure
Study design Approval was obtained from the University of Pennsylvania Institutional Review Board (IRB, protocol # 819121) and the Abramson Cancer Center Clinical Trials Scientific Review Committee (CTSRMC, UPCC # 33113) for this study
Summary
With the incidence of breast cancer rising worldwide, we are evaluating the iBreastExam (iBE) (UE LifeSciences Inc.), a handheld breast scanning device that can be utilized by community health workers to screen for breast abnormalities. The incidence of breast cancer is rising rapidly worldwide. Since 2008, the incidence of breast cancer has increased by more than 20 % worldwide [1]. The iBreastExam (iBE) device was developed as a pre-screening tool that could identify women in need of further breast imaging without requiring extensive breast screening infrastructure. This inexpensive handheld device uses piezoelectric palpation to enhance the clinical breast exam (CBE) for detection of breast masses that require further investigation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
